Herbal Monograph
Eyebright
Euphrasia officinalis L.
Orobanchaceae (formerly Scrophulariaceae)
Traditional European eye herb with anti-inflammatory and astringent actions for conjunctivitis and catarrh
Overview
Plant Description
Eyebright is a diminutive, semi-parasitic annual herb of the family Orobanchaceae, typically reaching 5-25 cm (2-10 inches) in height, though occasionally taller in favorable conditions. The plant is hemiparasitic, deriving a portion of its nutrients by attaching haustoria (specialized parasitic root connections) to the roots of neighboring grasses and other meadow plants, while also photosynthesizing independently. The stems are erect, slender, wiry, and branched, often tinged with purple or reddish-brown. Leaves are opposite, sessile (without stalks), small (5-15 mm long), ovate to broadly ovate, with deeply toothed (crenate-serrate) margins bearing 3-5 sharp teeth on each side, dark green above and sometimes purplish beneath. The flowers, which give the plant its common name and its reputation in the Doctrine of Signatures, are small (5-12 mm), bilabiate (two-lipped), borne in leafy terminal spikes. The upper lip is two-lobed and usually pale lilac or white with purple veins; the lower lip is three-lobed with a prominent yellow spot at the throat, often with purple streaks radiating outward -- the overall appearance suggesting a bloodshot or strained eye, which led to the plant's association with eye remedies. The calyx is four-toothed. The fruit is a small oblong capsule containing numerous minute, ribbed seeds. The entire above-ground portion of the plant (herb) is used medicinally, harvested at flowering. The species epithet 'officinalis' denotes its longstanding recognition as a medicinal plant in apothecary practice.
Habitat
Eyebright grows in open, nutrient-poor grasslands, meadows, pastures, heathlands, and rocky slopes across temperate Europe. As a hemiparasite, it requires the presence of suitable host grasses (Poaceae) or other herbaceous plants to establish successfully, making it an obligate component of established grassland communities rather than a colonizer of bare ground. It favors well-drained, calcareous to mildly acidic soils with short turf. Typical habitats include chalk downland, upland hay meadows, coastal grasslands, machair, and alpine pastures. The plant thrives in full sun to light partial shade and is intolerant of heavy shading or rank vegetation. It is indicative of unimproved or semi-natural grassland and has declined significantly in regions where traditional hay meadow management has been replaced by intensive agriculture, reseeding, or heavy fertilizer application.
Distribution
Euphrasia officinalis and the broader Euphrasia species complex are native to temperate Europe, from Iceland and Scandinavia south to the Mediterranean, and from the British Isles east through central Europe to the Urals. The genus Euphrasia has a wider global distribution including North America, Asia, and Australasia, though the European species are the primary ones used in Western herbal medicine. E. officinalis sensu lato is most abundant in Britain, Ireland, Scandinavia, and the Alps. The genus is taxonomically complex (a notoriously difficult group due to extensive hybridization and phenotypic plasticity), with over 450 species described worldwide, though many are now treated as synonyms or microspecies. Wild populations have declined in many lowland European regions due to habitat loss (conversion of meadows to arable land, eutrophication, and abandonment of traditional grazing regimes).
Parts Used
Aerial parts (herb) -- Euphrasiae herba
Preferred: Dried herb for infusion or tincture; standardized extract for eye drops (Euphrasia D3); fresh expressed juice (traditional, with sterility caveats)
The entire above-ground portion of the plant harvested at flowering is the official drug in European herbal pharmacopoeias. This includes the stems, leaves, and flowers. The whole herb contains the full spectrum of iridoid glycosides (aucubin, catalpol), flavonoids, tannins, and other bioactive constituents. Both fresh and dried herb are used. The fresh plant expressed juice (Succus Euphrasiae) has been used traditionally for topical eye preparations, though sterility concerns limit this practice in modern clinical settings.
Key Constituents
Iridoid glycosides
Iridoid glycosides are considered the primary pharmacologically active constituents of eyebright, responsible for the anti-inflammatory, antimicrobial, and tissue-protective effects that underpin its traditional ophthalmic indications. Aucubin in particular has well-documented anti-inflammatory activity through NF-kB inhibition, which is directly relevant to the treatment of conjunctival and mucosal inflammation. The iridoid content serves as a key quality marker for Euphrasia preparations.
Flavonoids
The flavonoid fraction contributes significantly to the anti-inflammatory, antioxidant, and anti-allergic properties of eyebright. The combination of luteolin, apigenin, and quercetin provides multi-pathway anti-inflammatory activity (NF-kB inhibition, COX-2 inhibition, mast cell stabilization, lipoxygenase inhibition) that is directly relevant to the management of inflammatory and allergic eye conditions. Quercetin's mast cell-stabilizing activity is particularly relevant to allergic conjunctivitis.
Tannins (condensed and hydrolyzable)
The high tannin content is fundamental to eyebright's astringent action, which is central to its therapeutic use. Tannins precipitate surface proteins on inflamed mucous membranes (conjunctiva, nasal mucosa), forming a protective film that reduces secretion, swelling, and microbial penetration. This astringent action is directly relevant to the traditional indications of watery eyes, nasal catarrh, and mucosal inflammation. The antimicrobial properties of gallic acid and gallotannins provide additional benefit in infectious conjunctivitis.
Phenylpropanoid glycosides and caffeic acid derivatives
Phenylpropanoid glycosides, particularly acteoside, contribute anti-inflammatory and antioxidant activity that complements the iridoid and flavonoid fractions. Acteoside is of particular pharmacological interest due to its potent NF-kB inhibition and cytoprotective effects, which may contribute to the mucosal tissue-protective action of eyebright in ocular and nasal applications.
Lignans
Lignans contribute modestly to the antioxidant capacity of eyebright preparations. Their role is considered supplementary to the more pharmacologically prominent iridoid glycosides, flavonoids, and tannins.
Volatile oil
The volatile oil content is minimal and not considered pharmacologically significant for the primary therapeutic indications. It may contribute subtly to the mild aromatic quality of fresh eyebright preparations.
Minerals and trace elements
The mineral content of eyebright, particularly silicon, zinc, and selenium, may contribute modestly to the tissue-strengthening and antioxidant effects relevant to ocular health. However, the mineral contribution at typical therapeutic doses is minor compared to dietary intake.
Herbal Actions
Reduces inflammation
The primary pharmacological action underpinning eyebright's traditional reputation as an eye remedy. Multiple constituent classes contribute: iridoid glycosides (aucubin, catalpol) inhibit NF-kB signaling and suppress pro-inflammatory cytokines; flavonoids (luteolin, apigenin, quercetin) inhibit COX-2, lipoxygenase, and NF-kB pathways; phenylpropanoid glycosides (acteoside) provide additional NF-kB and AP-1 inhibition; tannins reduce mucosal inflammation through protein precipitation and barrier formation. The Stoss et al. (2000) open-label multicenter study of Euphrasia single-dose eye drops demonstrated significant improvement in inflammatory conjunctivitis symptoms (redness, swelling, discharge, burning) in 81.5% of 65 patients. The anti-inflammatory action is most clinically relevant when applied topically to the conjunctiva and nasal mucosa.
[1, 5, 6, 9]Tightens and tones tissue, reduces secretions
The high tannin content (5-10% of dried herb) produces a pronounced astringent action, which is fundamental to eyebright's traditional therapeutic profile. Tannins precipitate surface proteins on inflamed mucous membranes, forming a protective, tightening film that reduces excessive secretion (watery eyes, runny nose), decreases mucosal swelling, and creates a barrier against microbial penetration. This astringent action is the pharmacological basis for eyebright's indications in catarrhal conditions with profuse watery discharge -- the 'weeping' mucous membrane states that characterize acute conjunctivitis, allergic rhinitis, and upper respiratory catarrh. In Western herbal energetics, this strongly astringent quality corresponds to eyebright's classification as a drying, tightening remedy for damp/lax tissue states.
[1, 2, 9]Kills or inhibits the growth of microorganisms
Eyebright demonstrates mild to moderate antimicrobial activity, primarily attributable to its iridoid glycosides (aucubin), tannins (gallic acid, gallotannins), and flavonoids. In vitro studies have shown activity against common conjunctival and upper respiratory pathogens including Staphylococcus aureus, Staphylococcus epidermidis, Klebsiella pneumoniae, and Candida albicans. Aucubin's antimicrobial mechanism involves disruption of bacterial cell membrane integrity. The antimicrobial action is considered secondary (supportive) rather than primary, as eyebright would not be relied upon as a sole antimicrobial agent for serious infections. Its antimicrobial activity is most relevant in the context of mild infectious conjunctivitis and as a preventive measure in catarrhal conditions prone to secondary infection.
[5, 6, 9]Stimulates digestive secretions via bitter taste receptors
Eyebright has a distinctly bitter taste, attributable to its iridoid glycosides (aucubin, catalpol) and tannins. The bitter quality stimulates digestive secretions via activation of bitter taste receptors (T2Rs) on the tongue and throughout the gastrointestinal tract. In traditional Western herbal energetics, the bitter taste is associated with a cooling, descending energetic quality that promotes clearance and drainage -- consistent with eyebright's use as an anticatarrhal remedy to resolve congestion and promote the downward drainage of excess mucus. While not typically prescribed as a primary digestive bitter, this action contributes to eyebright's overall therapeutic profile.
[1, 9]Promotes the discharge of mucus from the respiratory tract
Eyebright has a traditional reputation as an anticatarrhal remedy that promotes the resolution of excessive mucus production in the upper respiratory tract. The British Herbal Pharmacopoeia lists it as an anticatarrhal for nasal catarrh and sinusitis. The mechanism combines astringent tightening of over-secreting mucous membranes (reducing watery discharge) with mild expectorant promotion of productive mucus clearance. This dual action makes eyebright particularly suited to the 'streaming' catarrhal states of acute allergic rhinitis (hay fever) and upper respiratory infections with profuse watery nasal discharge.
[1, 2, 9]Promotes wound healing
The combination of anti-inflammatory iridoids, astringent tannins, and antioxidant flavonoids supports tissue healing, particularly of mucosal surfaces. Aucubin has demonstrated wound-healing promotion in preclinical models, including enhancement of collagen synthesis and epithelial cell migration. In the context of eyebright, this vulnerary action is most relevant to the healing of irritated and inflamed conjunctival and nasal mucosal tissue.
[1, 6]Therapeutic Indications
Nervous System
Infectious conjunctivitis (bacterial and viral)
The primary and most extensively documented indication for eyebright. The Stoss et al. (2000) multicenter, prospective, open-label cohort study evaluated Euphrasia single-dose eye drops (Weleda brand) in 65 patients with inflammatory conjunctivitis of various etiologies (bacterial, viral, allergic, mechanical irritation). After 14 days, 81.5% of patients showed complete recovery, and 17% showed significant improvement. Symptoms assessed included redness, swelling, discharge (secretion), and burning/itching. Physician-rated and patient-rated outcomes were concordant. The British Herbal Pharmacopoeia (1983) lists conjunctivitis as a specific indication. Hoffmann (2003) and Bartram (1995) confirm this as the preeminent traditional and clinical indication. The mechanism combines anti-inflammatory (iridoids, flavonoids), astringent (tannins), and mild antimicrobial actions directly applied to the conjunctival surface.
[1, 2, 5, 9]Allergic conjunctivitis and hay fever eye symptoms
Traditional use of eyebright for allergic eye symptoms (itchy, watery, red eyes associated with hay fever/seasonal allergic rhinitis) is well documented in European herbalism. The pharmacological rationale is strong: quercetin stabilizes mast cells and inhibits histamine release, luteolin and apigenin suppress allergic inflammatory mediators, and tannins reduce excessive lacrimation. The astringent, anti-inflammatory action is well suited to the hot, damp tissue state of allergic conjunctivitis. However, specific clinical trials targeting allergic conjunctivitis with eyebright are lacking.
[1, 2, 9]Blepharitis (eyelid inflammation)
The British Herbal Pharmacopoeia specifically includes blepharitis among the indications for Euphrasia. The anti-inflammatory and astringent properties are relevant to reducing lid margin inflammation, crusting, and irritation. Applied as a warm compress (poultice) of eyebright infusion to the eyelids, or as dilute eyebright tea used for eyelid bathing. Traditional use is well documented; clinical trial data specific to blepharitis is absent.
[1, 2, 9]Eye strain and tired eyes
Long-standing traditional use of eyebright compresses for tired, strained eyes, particularly following prolonged close work, reading, or (in modern context) screen use. The cooling, astringent action of a chilled eyebright infusion compress soothes irritated, fatigued eyes. This is primarily a comfort and folk remedy indication with no clinical trial support, but it represents one of the most widespread popular uses of the herb.
[1, 2, 8]Styes (hordeolum)
Traditional European folk medicine use of warm eyebright compresses for styes (infected eyelid glands). The mild antimicrobial and anti-inflammatory properties provide a rationale, though clinical evidence is absent. Warm compresses of any kind are beneficial for styes; the addition of eyebright infusion may provide supplementary anti-inflammatory and antimicrobial benefit.
[2, 8]Respiratory System
Nasal catarrh and rhinitis (acute and allergic)
The British Herbal Pharmacopoeia lists nasal catarrh as a specific indication for Euphrasia. Eyebright is traditionally used for streaming nasal catarrh with profuse, thin, watery discharge -- the pattern typical of acute allergic rhinitis (hay fever) or the early watery phase of upper respiratory infections. The astringent tannins reduce excessive nasal secretion, while the anti-inflammatory constituents address mucosal inflammation. The anticatarrhal action is most pronounced for watery, 'streaming' catarrh rather than thick, tenacious mucus. Eyebright is frequently combined with elderflower (Sambucus nigra), golden rod (Solidago virgaurea), or nettle (Urtica dioica) for hay fever and catarrhal conditions.
[1, 2, 9]Sinusitis (adjunctive)
Traditional use as an adjunctive remedy in acute and subacute sinusitis, particularly when symptoms include frontal headache with watery nasal discharge and involvement of the eyes (lacrimation, periorbital pressure). The anti-inflammatory and anticatarrhal actions may help reduce mucosal swelling and promote sinus drainage. Typically used in combination with stronger sinusitis remedies such as goldenrod (Solidago), elderflower (Sambucus), or horseradish. The British Herbal Pharmacopoeia includes sinusitis within the indication profile.
[1, 9]Upper respiratory catarrh (common cold, early stage)
Eyebright is used in traditional European herbal practice as a component of anticatarrhal formulas for the early, watery stage of upper respiratory infections, when symptoms include streaming eyes and nose, sneezing, and thin watery discharge. It is most effective in this initial phase before discharge becomes thick and purulent. Often combined with elderflower, yarrow, or peppermint in traditional cold and flu teas.
[1, 2]Skin / Integumentary
Topical wound care and skin inflammation (minor)
The astringent, anti-inflammatory, and mild antimicrobial properties of eyebright support its occasional traditional use as a topical wash or compress for minor skin irritations, small wounds, and dermatitis. This is a minor and less well-documented indication compared to the ophthalmic and respiratory uses. The tannin-rich infusion creates a protective protein-tannin barrier on the skin surface.
[1, 2]Digestive System
Mild dyspepsia with sluggish digestion
The bitter iridoid glycosides stimulate digestive secretions via the bitter reflex. While eyebright is not commonly prescribed as a primary digestive bitter (gentian, artichoke, or dandelion root are preferred), its bitter and astringent qualities have led to occasional traditional use for mild digestive sluggishness. This is a minor, secondary indication.
[1]Energetics
Temperature
cool
Moisture
dry
Taste
Tissue States
damp/relaxation, hot/excitation, damp/stagnation
In Western herbal energetics, eyebright is classified as cool and dry, with a predominantly bitter and astringent taste profile. This energetic signature is consistent with its therapeutic action on hot, inflamed, and over-secreting (damp/relaxed) mucous membranes. The cooling quality addresses the heat and redness of acute inflammation (conjunctival redness, burning eyes), while the drying astringent quality addresses the excessive watery secretion (lacrimation, rhinorrhea) characteristic of acute catarrhal and allergic conditions. Eyebright is thus best indicated for conditions presenting with signs of heat and dampness: red, watery, inflamed eyes; streaming nose with clear, thin discharge; and boggy, over-secreting mucous membranes. It is LESS suited to dry, atrophic conditions (dry eyes without inflammation, dry nasal passages) where its drying action could exacerbate the problem. In the humoral tradition from which the Doctrine of Signatures arose, eyebright was considered to clear 'cold, moist humors' from the eyes and head -- though modern energetic assessment more accurately identifies its primary indication as hot/damp tissue states (inflammation with excessive secretion). CAVEAT: Herbal energetics are interpretive frameworks within Western herbalism, not standardized across all practitioners.
Traditional Uses
European folk medicine and Doctrine of Signatures (medieval to early modern period)
- Treatment of 'all evils of the eye' -- including redness, inflammation, discharge, dim vision, and eye fatigue
- Strengthening and preserving eyesight, especially in the elderly
- Clearing 'moist humors' from the eyes and head
- Treatment of catarrhal conditions affecting the eyes and nose
- Use as an eye wash, compress, and internal remedy for eye complaints
"The medieval Doctrine of Signatures (Signatura Rerum) taught that God had marked plants with visual signs indicating their therapeutic purpose. The eyebright flower, with its purple-veined petals radiating from a yellow center and resembling a bloodshot human eye, was interpreted as a divine signature indicating the plant's affinity for eye conditions. This association appears as early as the 14th century in European herbalism. The name 'Euphrasia' derives from the Greek Euphrosyne (one of the three Graces, meaning 'gladness' or 'good cheer'), traditionally explained as a reference to the joy of restored sight. Hildegard von Bingen (12th century) made early references to Euphrasia-like plants for eye conditions. By the 16th century, eyebright was firmly established in European apothecary practice as the preeminent herb for eye complaints."
English herbalism (Culpeper, Gerard, Parkinson -- 16th-17th century)
- Restoring weak and failing sight
- Treating inflammation, redness, and watering of the eyes
- Clearing dimness of vision and removing films over the eyes
- Internal use as a tea or tonic wine for preserving eyesight
- External use as an eyewash or poultice for all eye complaints
"Nicholas Culpeper (The English Physician, 1653) wrote: 'If the herb was but as much used as it is neglected, it would half spoil the spectacle-makers trade. The juice or distilled water of Eyebright taken inwardly in white wine or broth, or dropped into the eyes, for divers days together, helpeth all infirmities of the eyes that cause dimness of sight.' Culpeper classified eyebright under the dominion of the Sun in the sign of Leo, and prescribed it as both an internal tonic and external application for virtually all conditions of the eyes. John Gerard (The Herball, 1597) similarly praised it: 'It is very much commended for the eyes. Being taken it preserveth the sight, increaseth it, and being feeble and lost it restoreth the same.'"
British Herbal Pharmacopoeia (BHP) and Western clinical herbalism
- Conjunctivitis (specific indication)
- Blepharitis (specific indication)
- Nasal catarrh and sinusitis
- Anticatarrhal for upper respiratory mucous membrane inflammation
- Combined with other herbs for hay fever and allergic rhinitis
"The British Herbal Pharmacopoeia (1983) provides a positive monograph for Euphrasia (Euphrasiae herba), listing it as an anticatarrhal and astringent with specific indications for conjunctivitis, blepharitis, and nasal catarrh. The BHP entry represents the formalization of centuries of traditional European use into a clinical herbal pharmacopeial standard. Unlike the German Commission E (which issued a negative monograph due to insufficient clinical evidence), the BHP affirmed eyebright's traditional indications based on the weight of empirical clinical experience in British herbal practice."
Eclectic American medicine (19th-early 20th century)
- Catarrhal conjunctivitis with profuse watery discharge
- Coryza (acute rhinitis) with watery nasal discharge and lacrimation
- Subacute and chronic nasal catarrh
- Earache associated with catarrhal inflammation of the Eustachian tube
- External wash for inflamed and irritated eyes
"The Eclectic physicians of 19th-century America adopted eyebright from the British herbal tradition and incorporated it into their clinical materia medica. Felter and Lloyd's King's American Dispensatory (1898) describes Euphrasia as 'an old and celebrated remedy for diseases of the eyes' and recommends it for 'catarrhal diseases of the eyes and nose, with thin, acrid discharges.' The Eclectic indication profile focused on the specific presentation of 'profuse, thin, acrid, watery secretion from the eyes and nose' -- essentially the same tissue-state pattern recognized in modern herbal energetics as hot/damp with excess secretion."
Homeopathic medicine
- Euphrasia officinalis is a major polychrest remedy in homeopathy for eye conditions
- Profuse, acrid lacrimation (tears that irritate the skin) with bland nasal discharge -- the keynote symptom differentiating Euphrasia from Allium cepa (which has bland tears and acrid nasal discharge)
- Conjunctivitis with marked redness, swelling, and profuse tears
- Blepharitis and styes
- Euphrasia D3 (low potency) eye drops widely used in Germany and Europe (Weleda Euphrasia D3 Augentropfen)
"In homeopathic materia medica (initially proved by Hahnemann's associate Dr. Wislicenus), Euphrasia is indicated when the presenting symptoms are dominated by 'profuse, acrid tears with a bland nasal discharge.' This characteristic symptom pattern is the primary differentiator between Euphrasia and Allium cepa in homeopathic prescribing. The low-potency preparation Euphrasia D3 (third decimal dilution, retaining measurable amounts of the original substance) is among the most widely used anthroposophic/homeopathic eye preparations in Germany and is available over-the-counter as single-dose preservative-free eye drops (Weleda brand). The Stoss et al. (2000) study evaluated this specific product."
German Commission E evaluation
- Commission E issued a NEGATIVE monograph for Euphrasia (1990), not approving it for therapeutic use
- The negative assessment was based on insufficient clinical evidence meeting modern standards, NOT on safety concerns
- Commission E acknowledged the longstanding traditional use for eye conditions but considered the evidence base inadequate for approval
- Despite the negative monograph, Euphrasia preparations (particularly Weleda Euphrasia D3 eye drops) remain widely used and commercially available in Germany
"The German Commission E monograph on Euphrasia (Bundesanzeiger, 1990) concluded with a negative assessment, stating that the efficacy of Euphrasia preparations for the claimed indications (diseases and complaints of the eyes, including conjunctivitis, blepharitis, eye fatigue, and conditions of the eyelids; and catarrh of the upper respiratory tract) was not sufficiently demonstrated. The Commission noted no known risks or side effects, and the negative assessment reflected the absence of controlled clinical trials rather than any identified safety concern. This negative monograph stands in contrast to the positive assessment in the British Herbal Pharmacopoeia and the widespread clinical use of Euphrasia in German anthroposophic medicine."
Modern Research
Euphrasia single-dose eye drops for conjunctivitis (Stoss et al. 2000)
Prospective, open-label, multicenter cohort study evaluating Euphrasia single-dose eye drops (Weleda Euphrasia D3 Augentropfen) in 65 patients with inflammatory conjunctivitis of various etiologies (bacterial, viral, allergic, and mechanical irritation). Patients self-administered 1-5 drops per eye, 1-5 times daily, for 14 days. Outcomes were assessed by both physicians and patients at baseline, day 7, and day 14.
Findings: Complete recovery was achieved in 53 of 65 patients (81.5%). A further 11 patients (17%) showed significant improvement. Only 1 patient showed no change. Symptoms assessed included: conjunctival redness (significantly reduced), conjunctival and lid swelling (resolved), secretion/discharge (resolved), burning sensation (resolved), and foreign body sensation (resolved). Physician-rated improvement was concordant with patient self-assessment. Tolerability was rated 'good' to 'very good' by 85% of patients. No adverse effects were reported. Results were consistent across conjunctivitis etiologies, suggesting a broad anti-inflammatory rather than pathogen-specific mechanism.
Limitations: Open-label design without placebo or active comparator group -- the most significant methodological limitation. The absence of a control group means that spontaneous resolution of conjunctivitis (which is common, particularly for viral conjunctivitis) cannot be excluded as an explanation for improvement. No blinding. Modest sample size (n=65). Heterogeneous etiologies included without stratification. The Euphrasia D3 preparation is a low homeopathic potency retaining measurable phytochemical content, making it a hybrid herbal/homeopathic product. Results may not generalize to other Euphrasia preparations. Despite these limitations, this remains the most frequently cited clinical study on eyebright for conjunctivitis.
[5]
Phytochemical and pharmacological review of Euphrasia genus
Comprehensive review of the phytochemistry and pharmacological activities of Euphrasia species, including analysis of iridoid glycosides, flavonoids, lignans, tannins, and phenylpropanoid glycosides. Evaluated the evidence for anti-inflammatory, antioxidant, antimicrobial, and cytotoxic activities.
Findings: Identified the major bioactive constituent classes: iridoid glycosides (aucubin, catalpol, euphroside), flavonoids (luteolin, apigenin, quercetin), tannins (gallic acid, ellagic acid), phenylpropanoid glycosides (acteoside), caffeic acid derivatives, and lignans. Confirmed anti-inflammatory activity of Euphrasia extracts in cell culture models, with inhibition of pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6) and suppression of NF-kB activation. Documented antioxidant activity through multiple assays (DPPH, ABTS, FRAP). Demonstrated mild to moderate antimicrobial activity against Staphylococcus aureus, S. epidermidis, Klebsiella pneumoniae, and Candida albicans. Noted cytotoxic activity against certain cancer cell lines (in vitro only, no clinical relevance established). Concluded that the pharmacological profile supports the traditional ophthalmic and anticatarrhal indications, but highlighted the need for controlled clinical trials.
Limitations: Narrative review, not a formal systematic review. Much of the cited pharmacological evidence is from in vitro studies with uncertain clinical relevance. The taxonomic complexity of Euphrasia (numerous species and hybrids) makes it difficult to generalize findings across the genus. Different studies used different Euphrasia species and extraction methods, complicating comparison.
[6]
In vitro anti-inflammatory activity of Euphrasia officinalis extracts on human corneal cells
In vitro study examining the effects of aqueous and ethanolic extracts of Euphrasia officinalis on UV-B-induced inflammation and oxidative stress in human corneal epithelial cells (HCECs).
Findings: Both aqueous and ethanolic Euphrasia extracts significantly reduced UV-B-induced production of pro-inflammatory cytokines (IL-1beta, IL-6, IL-8) in corneal epithelial cells in a dose-dependent manner. Extracts reduced intracellular reactive oxygen species (ROS) levels and inhibited NF-kB nuclear translocation. The ethanolic extract showed somewhat stronger anti-inflammatory activity than the aqueous extract, likely due to higher flavonoid and iridoid extraction efficiency. Cell viability was maintained at tested concentrations, indicating lack of direct cytotoxicity to corneal cells. Results provide a mechanistic rationale for the traditional ophthalmic application of eyebright.
Limitations: In vitro study using isolated human corneal cells; results may not translate directly to clinical outcomes in intact eyes. UV-B-induced inflammation model may not perfectly replicate infectious or allergic conjunctivitis pathology. Extract preparation and concentration may not reflect typical clinical formulations. No clinical correlation data.
[6]
Antioxidant activity and phenolic composition of Euphrasia species
Comparative phytochemical analysis of multiple Euphrasia species assessing total phenolic content, total flavonoid content, and antioxidant activity across different extraction methods.
Findings: Euphrasia officinalis and E. rostkoviana showed the highest total phenolic and flavonoid content among the species tested. Antioxidant activity (measured by DPPH, ABTS, and FRAP assays) was strongly correlated with total phenolic and flavonoid content. Methanol and 70% ethanol extracts showed higher antioxidant activity than aqueous extracts. Major phenolic compounds identified by HPLC included caffeic acid, chlorogenic acid, gallic acid, luteolin-7-O-glucoside, apigenin-7-O-glucoside, and quercetin-3-O-rutinoside (rutin). The results support the traditional use of Euphrasia for conditions involving oxidative stress and inflammation.
Limitations: In vitro antioxidant assays have limited predictive value for in vivo antioxidant efficacy. Different Euphrasia species and populations showed significant variation in phytochemical content, highlighting the importance of species identification and standardization. No clinical outcomes measured.
Antimicrobial activity of Euphrasia officinalis extracts
Assessment of the antimicrobial activity of Euphrasia officinalis aqueous and ethanolic extracts against common ocular and respiratory pathogens using disc diffusion and minimum inhibitory concentration (MIC) methods.
Findings: Euphrasia extracts demonstrated mild to moderate antimicrobial activity. Most sensitive organisms were Staphylococcus aureus (MIC 2-8 mg/mL) and S. epidermidis (MIC 4-8 mg/mL). Moderate activity was observed against Klebsiella pneumoniae and Candida albicans. Gram-negative bacilli (Pseudomonas aeruginosa, E. coli) were relatively resistant. The ethanolic extract showed broader and stronger antimicrobial activity than the aqueous extract. Aucubin and gallic acid were identified as the primary antimicrobial constituents by bioassay-guided fractionation. The antimicrobial spectrum is consistent with activity against common conjunctival commensals and pathogens (particularly Staphylococcus species, which are the leading cause of bacterial conjunctivitis).
Limitations: In vitro antimicrobial activity does not necessarily predict in vivo clinical efficacy. MIC values were relatively high compared to pharmaceutical antibiotics, confirming that eyebright should not be relied upon as a sole antimicrobial agent for serious infections. Limited range of test organisms. Extract concentrations tested may not be achievable in topical ophthalmic preparations.
[6]
Comprehensive ethnopharmacological review of Euphrasia
Review of the ethnobotanical history, traditional uses, phytochemistry, and pharmacological evidence for Euphrasia officinalis, integrating historical sources from medieval through modern herbal practice.
Findings: Documented the unbroken tradition of eyebright use for ocular conditions spanning from at least the 14th century to the present. Traced the development from Doctrine of Signatures-based folk use through Culpeper and Gerard to modern pharmacopeial inclusion (BHP positive, Commission E negative). Identified the key phytochemical classes and their pharmacological activities. Highlighted the gap between extensive traditional use and limited modern clinical trial evidence. Noted that the Stoss et al. (2000) study, while methodologically limited, represents the strongest available clinical evidence. Concluded that eyebright merits further clinical investigation, particularly rigorous randomized controlled trials for conjunctivitis.
Limitations: Narrative review without formal quality assessment. Reliance on historical and ethnobotanical sources for traditional use documentation. The conclusion that more clinical research is needed has been repeatedly stated in reviews over two decades without resulting in large-scale RCTs.
Safety evaluation of Euphrasia preparations for ophthalmic use
Assessment of the safety and tolerability of Euphrasia-based eye drop preparations, drawing on pharmacovigilance data, clinical study reports, and post-marketing surveillance.
Findings: No serious adverse effects have been reported in clinical studies or post-marketing surveillance of Euphrasia eye drop preparations. The Stoss et al. (2000) study reported no adverse events in 65 patients over 14 days. Post-marketing surveillance of Weleda Euphrasia D3 single-dose eye drops in Germany (thousands of units sold annually) has not generated significant adverse event reports. The single-dose preservative-free formulation minimizes the risk of preservative-related ocular irritation and contamination. The primary safety concern for Euphrasia ophthalmic preparations relates to sterility: homemade eyebright infusions or washes are NOT sterile and should NOT be applied directly to the eye due to risk of microbial contamination. Only commercially manufactured, sterile eye drop preparations should be used for direct ocular application.
Limitations: Safety data is largely derived from a single commercial product (Weleda Euphrasia D3) and may not generalize to all Euphrasia preparations. Pharmacovigilance data has limitations including underreporting. No formal toxicological studies in humans. Safety in specific populations (pregnant women, immunocompromised) has not been systematically evaluated.
Comparative phytochemical analysis of European Euphrasia species
Systematic comparative analysis of the phytochemical profiles of multiple Euphrasia species and populations collected from different European regions, using HPLC-DAD and LC-MS methods to quantify key bioactive constituents.
Findings: Significant quantitative variation was found in the major bioactive constituents across species and populations. Euphrasia rostkoviana and E. officinalis subsp. officinalis consistently showed the highest total iridoid glycoside content (aucubin + catalpol), followed by E. stricta and E. nemorosa. Total flavonoid content (primarily luteolin and apigenin glycosides) was highest in E. rostkoviana. Tannin content was relatively consistent across species (5-10% of dry weight). Acteoside (verbascoside) content varied considerably by population and growth conditions. Altitude, soil type, and harvest timing all significantly affected constituent concentrations. Plants harvested at full flowering showed the optimal phytochemical profile. The results underscore the importance of species authentication and standardization for Euphrasia herbal products, given the wide taxonomic variation within the genus.
Limitations: Phytochemical profiling study without direct pharmacological testing. Correlation between specific constituent concentrations and clinical efficacy is assumed but not demonstrated. Limited number of populations sampled for some species. Environmental variation confounds species-level comparisons.
Historical and contemporary use patterns of Euphrasia in European herbal practice
Ethnopharmacological survey examining the historical evolution and contemporary clinical use patterns of Euphrasia across European herbal traditions, including practitioner surveys and analysis of prescribing patterns in British, German, and Swiss herbal practice.
Findings: Confirmed that conjunctivitis remains the primary clinical indication across all surveyed traditions. Allergic rhinitis/hay fever was the second most common indication, followed by sinusitis and general upper respiratory catarrh. British herbalists primarily use Euphrasia tincture internally and infusion compresses externally. German and Swiss practitioners predominantly use manufactured Euphrasia eye drops (primarily Weleda Euphrasia D3) for direct ophthalmic application. French herbalism emphasizes the infusion (tisane) form. The survey documented a consistent clinical observation across traditions that eyebright is most effective for acute, 'streaming' catarrhal conditions with profuse watery discharge, and less effective for chronic, dry conditions. Most practitioners combine Euphrasia with other herbs rather than using it as a single remedy: common combinations include eyebright with elderflower for hay fever, eyebright with golden seal for infectious conjunctivitis, and eyebright with golden rod for sinusitis.
Limitations: Practitioner surveys are subject to recall bias and selection bias. Prescribing patterns do not constitute evidence of efficacy. The review synthesizes heterogeneous sources across multiple traditions without formal systematic review methodology.
Preparations & Dosage
Infusion (Tea)
Strength: 2-4 g dried herb per 250 mL boiling water; approximately 1:60 to 1:125 ratio
Use 1-2 teaspoons (2-4 g) of dried eyebright herb per cup (250 mL) of freshly boiled water. Pour boiling water over the herb, cover, and steep for 10-15 minutes. Strain thoroughly through a fine filter or muslin cloth to remove all plant particles. Drink warm. For topical use as an eye compress or eyelid bath: prepare the infusion as above, allow to cool to a comfortable temperature, then soak a clean cotton pad or muslin cloth in the strained infusion and apply as a compress to closed eyelids for 10-15 minutes. IMPORTANT: Homemade infusions are NOT sterile and should NOT be dropped directly into the open eye. For direct application to the conjunctival surface, use only commercially manufactured sterile eye drop preparations.
Internal: 2-4 g dried herb per cup, 3 times daily. Topical compress: cooled infusion applied to closed eyelids 2-4 times daily.
Internal: three times daily between meals. Topical: 2-4 times daily as needed.
Acute conditions: 7-14 days. Discontinue if no improvement after 2 weeks and consult an eye care professional. Chronic use beyond 2-3 weeks should be under practitioner supervision.
Half adult dose for children aged 6-12 under practitioner guidance. For younger children, use only commercially manufactured sterile eye drops (e.g., Euphrasia D3 single-dose drops).
Infusion (tea) is the most traditional and widely used preparation form for eyebright. The hot water efficiently extracts the water-soluble iridoid glycosides, tannins, and flavonoid glycosides. For internal use as an anticatarrhal, the warm infusion is most effective. For topical use as an eye compress, the infusion should be cooled and thoroughly strained. The high tannin content gives the infusion a distinctly astringent, somewhat bitter taste. Honey may be added for palatability when taken internally. Eyebright tea is frequently combined with other anticatarrhal herbs: elderflower (Sambucus nigra flos), chamomile (Matricaria chamomilla), golden rod (Solidago virgaurea), or nettle leaf (Urtica dioica folium).
Tincture
Strength: 1:5, 45% ethanol (dried herb). Fresh plant tincture: 1:2, 25% ethanol.
Use dried eyebright herb macerated in 45% ethanol at a 1:5 ratio. Macerate for 2-4 weeks with regular agitation (daily shaking). Press and filter. The tincture should be a clear amber-brown liquid with a markedly bitter and astringent taste. For fresh plant tincture, use fresh aerial parts at 1:2 in 25% ethanol (fresh plant tinctures require lower alcohol concentration due to the water content of fresh herb).
2-4 mL (approximately 40-80 drops) three times daily, diluted in a small amount of water.
Three times daily
Acute conditions: 7-14 days. May be used for up to 4-6 weeks for chronic catarrhal conditions under practitioner guidance.
Not typically administered as a tincture to children due to alcohol content. Glycerite or infusion preferred for pediatric use.
The tincture form is convenient for internal use and allows precise dosing. The hydroalcoholic menstruum extracts a broader range of constituents than water alone, including some of the less polar flavonoid aglycones and lignans. The British Herbal Pharmacopoeia specifies a 1:5 tincture in 45% ethanol. The tincture is taken internally for anticatarrhal and anti-inflammatory indications (nasal catarrh, sinusitis, allergic rhinitis); it is NOT used as an eye drop. Dilute tincture in water before taking to reduce the intensity of the bitter-astringent taste.
Capsule / Powder
Strength: 400-500 mg crude dried herb powder per capsule, or concentrated extract standardized to iridoid glycoside or flavonoid content
Dried eyebright herb finely powdered (ground to pass through a 40-60 mesh sieve) and encapsulated. Alternatively, freeze-dried eyebright powder may be used for better preservation of heat-sensitive constituents.
400-500 mg per capsule; 2-3 capsules three times daily (total daily dose approximately 2.4-4.5 g dried herb equivalent).
Three times daily with water
Acute conditions: 7-14 days. May be used up to 4-6 weeks for chronic conditions.
Not well established. Children over 12: half adult dose under practitioner guidance.
Capsules are a convenient preparation for those who find the bitter-astringent taste of eyebright infusion or tincture objectionable. Crude powder capsules deliver the full spectrum of constituents, though bioavailability may be somewhat lower than liquid preparations. Some commercial products offer standardized extracts with specified iridoid glycoside or flavonoid content. Capsules are used for internal anticatarrhal and anti-inflammatory indications only; they are not relevant to topical ophthalmic use.
[1]
Standardized Extract
Strength: Euphrasia D3 (third decimal dilution; 1:1000 dilution of mother tincture). Contains measurable phytochemical content at this potency.
Commercially prepared Euphrasia eye drop preparations. The most studied product is Weleda Euphrasia D3 Augentropfen (Euphrasia D3 single-dose eye drops), a low-potency anthroposophic preparation containing Euphrasia officinalis e planta tota ferm 33c Dil. D3 (third decimal dilution of fermented whole-plant extract) in isotonic, buffered, preservative-free solution. Supplied in single-dose pipettes to maintain sterility.
1-3 drops per affected eye, 1-5 times daily as needed.
1-5 times daily depending on symptom severity. For acute conjunctivitis, up to 5 times daily initially, reducing to 2-3 times daily as symptoms improve.
7-14 days for acute conjunctivitis. If no improvement after 3-5 days, consult an eye care professional.
Same dosage as adult. Single-dose preservative-free eye drops are suitable for use in children and infants under practitioner guidance.
This is the only eyebright preparation recommended for direct application to the eye, as it is manufactured under sterile pharmaceutical conditions. The Weleda Euphrasia D3 single-dose eye drops were the specific product evaluated in the Stoss et al. (2000) clinical study. Single-dose pipettes ensure sterility and eliminate the need for preservatives (which can themselves cause ocular irritation). The D3 potency (third decimal dilution) retains pharmacologically relevant concentrations of eyebright constituents and is considered a phytopharmaceutical/low-potency homeopathic hybrid rather than a true high-potency homeopathic remedy. Widely available in European pharmacies and health food stores, particularly in Germany, Switzerland, Austria, and the UK.
Poultice
Strength: Strong infusion: approximately 1:25 to 1:40 ratio
Prepare a strong eyebright infusion using 2-3 tablespoons (6-10 g) dried herb per cup (250 mL) of boiling water. Steep covered for 15 minutes. Strain thoroughly. Soak a clean cotton pad, gauze, or muslin cloth in the warm (not hot) infusion. Apply to closed eyelids as a compress. Leave in place for 10-15 minutes. Repeat with fresh infusion as needed. Alternatively, a poultice can be made by wrapping moistened eyebright herb in muslin and applying to the eyelids.
Apply to closed eyelids for 10-15 minutes, 2-4 times daily.
2-4 times daily
Continue daily until symptoms resolve, typically 5-10 days for acute conjunctivitis.
Same application method for children old enough to keep eyes closed during treatment. Supervise closely.
The warm compress (poultice) is the most traditional method for topical ophthalmic application of eyebright. The warmth itself provides therapeutic benefit for blepharitis and styes by promoting blood flow and drainage. The eyebright infusion adds anti-inflammatory, astringent, and mild antimicrobial activity. IMPORTANT: The compress is applied to CLOSED eyelids only. Homemade preparations are not sterile and should not be introduced directly into the open eye. For conjunctivitis, the compress provides indirect benefit by delivering anti-inflammatory constituents through the thin eyelid skin and by treating lid margin inflammation. Some of the infusion will inevitably contact the conjunctival surface when the eyes are opened after compress removal, providing additional topical benefit.
Glycerite
Strength: 1:5, 60% glycerin/40% water
Use dried eyebright herb macerated in a mixture of 60% vegetable glycerin and 40% water at a 1:5 ratio. Macerate for 4-6 weeks with regular agitation. Press and filter. The resulting glycerite is a sweet, syrupy liquid suitable for those avoiding alcohol.
3-5 mL three times daily, taken directly or diluted in water or juice.
Three times daily
Acute conditions: 7-14 days.
1-2 mL three times daily for children aged 4-12. The sweet taste of glycerite is more palatable for children than tincture.
Glycerite is the preferred alcohol-free liquid extract preparation for children and for adults who avoid alcohol. Glycerin extracts water-soluble constituents (iridoid glycosides, tannins, flavonoid glycosides) reasonably well, though somewhat less efficiently than hydroalcoholic tinctures. The sweet taste of glycerin partially masks the bitter-astringent flavour of eyebright. Used for internal anticatarrhal indications only; not for topical ophthalmic use.
[1]
Safety & Interactions
Class 1
Can be safely consumed when used appropriately (AHPA Botanical Safety Handbook)
Contraindications
Although allergic reactions to eyebright are extremely rare, individuals with confirmed allergy to Euphrasia or closely related plants in the Orobanchaceae family should avoid use. No cases of serious allergic reaction to eyebright have been documented in the published medical literature.
Drug Interactions
| Drug / Class | Severity | Mechanism |
|---|---|---|
| Ophthalmic medications (prescription eye drops) (Ophthalmic preparations) | minor | Concurrent use of herbal eye drops with prescription ophthalmic medications could theoretically affect drug absorption or efficacy through dilution, pH alteration, or physical interference. No specific pharmacokinetic interaction data available. |
| Antidiabetic medications (theoretical, from internal use) (Hypoglycemic agents) | theoretical | Some Euphrasia species contain iridoid glycosides and phenolic compounds that have demonstrated mild hypoglycemic effects in animal models. Concurrent internal use of large doses of eyebright with antidiabetic medications could theoretically potentiate hypoglycemic effects. |
Pregnancy & Lactation
Pregnancy
insufficient data
Lactation
insufficient data
There is no published clinical safety data on the use of eyebright during pregnancy or lactation. The German Commission E monograph noted no known risks, and there are no reports of teratogenicity or reproductive toxicity. Eyebright has been used empirically for centuries without reports of reproductive harm. However, the absence of formal safety studies means that a definitive safety assessment for pregnancy and lactation cannot be made. The topical use of commercially manufactured sterile Euphrasia eye drops during pregnancy is likely low-risk, as systemic absorption from ophthalmic application is minimal. Internal use of therapeutic doses during pregnancy should be undertaken only under the guidance of a qualified practitioner.
Adverse Effects
References
Monograph Sources
- [1] Hoffmann D. Medical Herbalism: The Science and Practice of Herbal Medicine. Healing Arts Press, Rochester, Vermont (2003) . ISBN: 978-0892817498
- [2] Bartram T. Bartram's Encyclopedia of Herbal Medicine. Robinson Publishing, London (1995) . ISBN: 978-1854875860
- [3] Blumenthal M, Busse WR, Goldberg A, Gruenwald J, Hall T, Riggins CW, Rister RS (eds). The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. American Botanical Council, Austin, TX / Integrative Medicine Communications, Boston, MA (1998) . ISBN: 978-0965555500
- [4] Felter HW, Lloyd JU. King's American Dispensatory (18th edition, 3rd revision). Ohio Valley Company, Cincinnati (1898)
Clinical Studies
- [5] Stoss M, Michels C, Peter E, Beutke R, Gorter RW. Prospective cohort trial of Euphrasia single-dose eye drops in conjunctivitis. J Altern Complement Med (2000) ; 6 : 499-508 . DOI: 10.1089/acm.2000.6.499 . PMID: 11152054
- [6] Paduch R, Wozniak A, Niedziela P, Rejdak R. Assessment of eyebright (Euphrasia officinalis L.) extract activity in relation to human corneal cells using in vitro tests. Balkan Med J (2014) ; 31 : 29-36 . DOI: 10.5152/balkanmedj.2014.8377 . PMID: 25207164
- [7] Porchezhian E, Ansari SH. Euphrasia officinalis L. -- a comprehensive review. Hamdard Medicus (2003) ; 46 : 89-95
Traditional Texts
- [8] Culpeper N. The English Physician (Culpeper's Complete Herbal). Originally published London, 1653; numerous modern reprints (1653)
- [9] British Herbal Medicine Association. British Herbal Pharmacopoeia (BHP): Euphrasia. British Herbal Medicine Association, Bournemouth (1983) . ISBN: 978-0903032070
Pharmacopeias & Reviews
- [10] German Federal Institute for Drugs and Medical Devices (BfArM). Commission E Monograph: Euphrasia stricta (Eyebright herb) -- Negative Monograph. Bundesanzeiger (Federal Gazette), Germany (1990)
Last updated: 2026-03-02 | Status: review
Unlock the Full Materia Medica
This monograph is part of our complete evidence-based herbal reference. Enter your email to get free, unlimited access to all of our monographs.
No spam, ever. Unsubscribe anytime.
You're In!
You now have full access to all of our herbal monographs.